- Home
- Labeler Index
- Ibsa Pharma Inc.
- 71858-0145
- FDA Recall: Tirosint Sol
FDA Recall Tirosint Sol
View Recall Number, Date, Reasons, Quantity
FDA Recall Enforcement Reports
The last Recall Enforcement Report for Tirosint Sol with NDC 71858-0145 was initiated on 01-30-2023 as a Class II recall due to subpotent drug The latest recall number for this product is D-0342-2023 and the recall is currently terminated as of 10-31-2023 .
| Recall Number | Initiation Date | Report Date | Recall Classification | Product Quantity | Product Description | Status |
|---|---|---|---|---|---|---|
| D-0342-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0135-5 | Terminated | |
| D-0333-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0140-5 | Terminated | |
| D-0344-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 150 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0150-5 | Terminated | |
| D-0345-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 200 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0160-5 | Terminated | |
| D-0337-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0113-5 | Terminated | |
| D-0338-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0115-5 | Terminated | |
| D-0334-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0155-5 | Terminated | |
| D-0332-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0130-5 | Terminated | |
| D-0340-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 75 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0120-5 | Terminated | |
| D-0331-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 13 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0105-5 | Terminated | |
| D-0343-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 137 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0145-5 | Terminated | |
| D-0339-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 62.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0117-5 | Terminated | |
| D-0335-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0110-5 | Terminated | |
| D-0336-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0112-5 | Terminated | |
| D-0341-2023 | 01-30-2023 | 03-01-2023 | Class II | TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0125-5 | Terminated |
What is the Enforcement Report?
All drug recalls are monitored by the Food and Drug Administration (FDA) and are included in the Enforcement Report once they are properly classified. The FDA will determine if a firm's removal or correction actions of a marked product meet the requirements to be considered a "recall". The FDA will also determine the public hazard assessment and a recall classification will be published in the Enforcement Report.
Recall Enforcement Report D-0342-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0342-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0135-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220414, Exp. 10/2023; 220852, Exp. 02/2024; 220970, Exp. 03/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0333-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0333-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0140-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220855, Exp. 2/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0344-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0344-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 150 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0150-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220959, Exp. 3/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0345-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0345-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 200 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0160-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220418, Exp. 10/2023; 220560, Exp. 11/2023. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0337-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0337-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0113-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220553, Exp. 11/2023; 221056, Exp. 04/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0338-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0338-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0115-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220407, Exp. 10/2023; 220960, Exp. 03/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0334-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0334-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0155-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220416, Exp. 10/2023; 221053, Exp. 4/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0332-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0332-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0130-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220413, Exp. 10/2023; 220964, Exp. 3/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0340-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0340-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 75 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0120-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220853, Exp. 02/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0331-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0331-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 13 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0105-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220409, Exp. 10/2023; 220956, Exp. 03/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0343-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0343-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 137 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0145-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220415, Exp. 10/2023; 221052, Exp. 04/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0339-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0339-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 62.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0117-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220556, Exp. 11/2023; 221058, Exp. 04/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0335-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0335-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0110-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220856, Exp. 2/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0336-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0336-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0112-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220552, Exp. 11/2023; 221055, Exp. 04/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
Recall Enforcement Report D-0341-2023
- Event ID
- 91556 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). - Recall Number
- D-0341-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). - Recall Classification
- Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". - Distribution Pattern
- Nationwide in the USA. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. - Product Description
- TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0125-5
- Reason For Recall
- Subpotent Drug What is the Reason for Recall?
Information describing how the product is defective. - Product Quantity
- Product Quantity
The amount of product subject to recall. - Voluntary Mandated
- Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. "Mandatory" designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. - Report Date
- 03-01-2023
- Recall Initiation Date
- 01-30-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall. - Termination Date
- 10-31-2023 What is the Date Terminated?
The date that FDA terminated the recall. - Initial Firm Notification
- Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall. - Product Type
- Drugs
- Recalling Firm
- IBSA PHARMA INC
- Code Info
- Lot #: 220411, Exp. 10/2023; 220854, Exp. 02/2024. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. - Recalled NDC Packages
- 71858-0105-6; 71858-0105-4; 71858-0105-5; 71858-0105-1; 71858-0110-6; 71858-0110-4; 71858-0110-5; 71858-0110-1; 71858-0112-6; 71858-0112-4; 71858-0112-5; 71858-0112-1; 71858-0113-6; 71858-0113-4; 71858-0113-5; 71858-0113-1; 71858-0115-6; 71858-0115-4; 71858-0115-5; 71858-0115-1; 71858-0117-6; 71858-0117-4; 71858-0117-5; 71858-0117-1; 71858-0120-6; 71858-0120-4; 71858-0120-5; 71858-0120-1; 71858-0125-6; 71858-0125-4; 71858-0125-5; 71858-0125-1; 71858-0130-6; 71858-0130-4; 71858-0130-5; 71858-0130-1; 71858-0135-6; 71858-0135-4; 71858-0135-5; 71858-0135-1; 71858-0140-6; 71858-0140-4; 71858-0140-5; 71858-0140-1; 71858-0145-6; 71858-0145-4; 71858-0145-5; 71858-0145-1; 71858-0150-6; 71858-0150-4; 71858-0150-5; 71858-0150-1; 71858-0155-6; 71858-0155-4; 71858-0155-5; 71858-0155-1; 71858-0160-6; 71858-0160-4; 71858-0160-5; 71858-0160-1
- Status
- Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.